Why Is UNIQURE N V (QURE) Stock Moving Today?

Why QURE stock is up today

uniQURE N.V. (QURE) shares rose 5.00% to $25.74 in the current session after a period of significant volatility. The recent four-year data from its AMT-130 Huntington’s disease trial triggered a sharp selloff earlier in the week, but the stock has since rebounded amid a mix of upgraded analyst ratings and a reaffirmed regulatory path for FDA approval.

What Happened

The stock’s recent selloff was driven by weaker-than-expected four-year data from uniQure’s AMT-130 trial, which showed a smaller benefit compared to the three-year result. This led to a price target cut from Goldman Sachs and a broader sell-off. However, the company clarified that the three-year data remains robust and the FDA has signaled openness to reviewing its BLA for AMT-130. This regulatory alignment prompted a rating upgrade to speculative Buy from Seeking Alpha, which helped reverse the downward momentum.

Analysts at RBC and Wells Fargo have also weighed in, with RBC calling the stock reaction "overdone" and Wells Fargo identifying the weakness as an attractive entry point. These developments, combined with a broader market environment that saw health care stocks move in Tuesday’s session, contributed to the current upward trend.

What The Data Shows

QURE opened the session at $24.47 and reached an intraday high of $26.68 at 9:45 AM ET before settling near $25.82. The stock is trading on 0.9 million shares so far, which is 0.5 times the 3-month daily average. Over the past 8 sessions, the stock has fallen 44.1% from $44.00 to $24.59. In the last 90 days, insiders have sold a total of $3.3 million in shares, with the most recent filing on July 7, 2026. Options activity has also been skewed toward puts, with the largest single print at $203,000.

What To Watch

The company is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments on the AMT-130 BLA timeline.

Why is QURE stock moving today?

UNIQURE N V (QURE) is drawing unusual attention today. Our newswire has captured 1 story on QURE across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "uniQure to Announce Third Quarter 2026 Financial Results" (Business Insider).

Is QURE a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of QURE coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.